单纯减压治疗伴Ⅰ度退变滑脱的腰椎管狭窄症的中远期疗效分析

目的：探讨椎板节段开窗减压治疗伴Ⅰ度退变性滑脱的腰椎管狭窄症患者的中远期疗效及相关影响因素.方法：回顾分析28例采用单纯椎板减压术治疗的伴Ⅰ度退变性滑脱的腰椎管狭窄症患者,男10例,女18例,年龄45～75岁,平均62岁,病程4个月～14年,平均18个月;滑脱节段L4 25例,L3 2例,L5 1例.评估患者术后平均2年与6.8年时的临床疗效.结果：术后平均2年和6.8年的JOA评估优良率分别为89.8%和76%;术前腰痛VAS评分平均7.6分,术后2年及6.8年分别为3.8和5.6分（P＜0.05）,腿痛VAS评分分别由术前8.2分下降至2.4和2.7分（P＜0.01）.影像学检查示滑脱节段椎间高度降低,滑脱轻度增加,椎体间活动度减少,但均无统计学差异.并发症3例,二次手术3例.结论：椎板节段开窗、椎管潜行扩大减压是治疗伴Ⅰ度退变性滑脱的腰椎管狭窄症的一种有效手术方法,远期疗效与手术方法、自然病程进展、相邻节段退变及腰椎不稳等多种因素有关.     

有限性椎板切除术治疗退行性腰椎管狭窄症

采用有限性椎板切除术治疗退行性腰椎管狭窄症68例,经术后平均27个月的随访,优良率94.1%.文中将退行性腰椎管狭窄症分为中央性腰椎管狭窄,侧隐窝狭窄,混合性狭窄.分别采用中央开窗、潜行扩大减压,一侧或双侧扩大开窗、侧隐窝扩大,蝶形扩大减压术.作者还对有限性椎板切除术的理论依据及减压范围进行了讨论.     

有限性椎板切除术治疗退行性腰椎管狭窄症

采用有限性椎板切除术治疗退行性腰椎管狭窄症６８例，经术后平均２７个月的随访，优良率９４．１％。文中将退行性腰椎管狭窄症分为中央性腰椎管狭窄，侧隐窝狭窄，混合性狭窄。分别采用中央开窗、潜行扩大减压，一侧或双侧扩大开窗、侧隐窝扩大，蝶形扩大减压术。作者还对有限性椎板切除术的理论依据及减压范围进行了讨论。     

后路椎间盘镜显微治疗腰椎椎管狭窄症

目的 报道显微后路椎间盘镜治疗退行性腰椎椎管狭窄症的临床效果。方法 选取退行性腰椎管狭窄症病例，椎板间隙入路椎间盘镜下行椎管减压，单侧单节段开窗减压23例，双侧单节段开窗减压12例，单侧双节段开窗减压9例，单侧双节段半椎板切除减压4例。结果 除1例术中硬膜破裂改常规手术外，其余病例均在手术显微镜下完成腰椎管减压术。所有病例获得5～18个月随访，平均8．3个月，优良率92％。结论 显微后路椎间盘镜治疗退行性腰椎管狭窄症具有手术创伤小、神经根减压彻底、术后恢复快的特点；单纯腰椎间盘膨出或突出、黄韧带肥厚和小关节增生引起的退行性腰椎管狭窄症是其适应证。     

退行性腰椎滑脱伴腰椎管狭症的手术治疗

目的探讨退变性腰椎滑脱伴椎管狭窄症的手术治疗。方法回顾性分析 84例退变性腰椎滑脱伴腰椎管狭窄症的手术治疗结果。其中男性 33例 ,女 5 1例 ;年龄 4 3～ 79岁 ,平均 5 6 .1岁 ;包括Ⅰ°滑脱 5 1例 ,Ⅱ°滑脱 33例。33例接受单侧或双侧椎板开窗减压术 ,5 1例接受全椎板切除减压、植骨融合椎弓根螺钉内固定术。结果 84例经过平均 5年 3个月的随访 ,两种手术方法疗效优良率分别是 90 .90 %、84 .2 7% ,两种疗效无显著性差别 (P >0 .0 5 )。手术并发症发生率为 9.0 9%、17.6 4 % ,亦无显著性差异 (P >0 .0 5 )。结论对于腰椎管狭窄症伴腰椎滑脱症手术适应症和减压范围要掌握恰当 ,二种手术方式减压均可以取得满意疗效。     

有限减压手术方式治疗退行性腰椎管狭窄症的疗效分析

目的观察有限减压手术治疗退行性腰椎管狭窄症的中远期疗效。方法98例退行性腰椎管狭窄症患者根据病理改变情况,分别采用三种手术方法(腰椎间盘镜下减压术、后路椎板开窗减压术与椎管环形减压术)进行有限减压。其中腰椎间盘镜下减压术29例,后路椎板开窗减压术22例,椎管环形减压术47例。所有患者未做融合及内固定术。采用Nakai分级结合腰椎正侧+动力位X线片所见,制定手术疗效判定标准。结果随访18个月~66个月,平均36.4个月。优86例(87%),良12例(13%),差0例(0%)。随访未发现手术节段失稳者。结论有限减压手术方式治疗不合并腰椎不稳及腰椎滑脱的退行性腰椎管狭窄症可取得良好的中远期疗效。     

全椎板切除减压内固定术治疗退行性腰椎管狭窄症

目的探讨腰椎后路全椎板切除减压,椎间自体植骨,椎弓根螺钉固定治疗退行性腰椎管狭窄症的疗效。方法 2006年3月~2009年7月收治退行性腰椎管狭窄症患者62例,所有患者均行腰椎后路全椎板切除减压,摘除相应节段的椎间盘,椎间植入自体骨,椎弓根螺钉固定减压节段。临床疗效采用JOA评分进行评估。结果 62例患者共减压134节段,固定134节段,所有减压节段均行椎间自体骨植骨。所有患者术后均获随访,平均21.3(15~34)个月。手术疗效根据日本骨科学会(JOA)下腰痛手术疗效标准(15分法)进行评分。62例患者中疗效达到优50例,良9例,可2例,差1例,优良率95.16%。结论腰椎后路全椎板切除减压椎间植骨椎弓根螺钉固定治疗退行性腰椎管狭窄症是一种有效的手术方法。     

椎板间开窗潜行减压治疗退行性腰椎管狭窄症(115例分析报告)

行椎板间开窗潜行减压治疗退行性腰椎管狭窄症115例,平均年龄54.2岁,病程平均3年9个月;全部病人都有腰痛和一侧或两侧下肢痛及麻木,均有间歇性跛行。除X线平片外,CT、CTM和/或MRI检查101例,椎管造影24例。其中伴椎间盘突出7例。狭窄段位于L_(4,5)49例,L_5S_125例,L_(3,4)3例,两个节段(L_(4,5)和L_5S_1或L_(4,5)和L_(3,4))26例,三个节段(L_(3,4),L_(4,5),L_5S_1)12例。术后复查CT/MRI 59例。结果84例获得随访,平均时间3年7个月,优51例,良27例,优良率91.66％。认为椎板间开窗潜行减压是治疗退行性腰椎管狭窄症的有效方法。该法简便、能维持后柱的稳定性。     

多节段开窗减压桥式成形术治疗退行性腰椎管狭窄症的疗效评价

目的探讨多节段开窗减压桥式成形术治疗退行性腰椎管狭窄症的疗效。方法采用经椎板间隙开窗减压桥式成形术扩大中央椎管和神经根管,并摘除突出之椎间盘治疗退行性腰椎管狭窄症共42例,其中单节段减压5例,双节段减压21例,3节段减压13例,4节段减压3例。结果42例随访6-79个月,根据JOA标准评定疗效：优12例,良24例,中4例,差2例（为发病前已有脊柱＂S＂形侧弯者）;优良率85.7%。发生硬膜撕裂1例,脑脊液漏2例。除1例椎间盘突出复发再行手术治疗外,无腰椎滑脱发生。结论多节段开窗减压桥式成形术治疗退行性腰椎管狭窄症不仅对各病变节段减压彻底,而且有效保护了腰椎生物力学结构,术式合理,疗效满意。     

双侧扩大开窗与全椎板切除治疗腰椎管狭窄症的疗效比较

我科自1994年对退行性腰椎管狭窄症(lumbarspinestenosis,LSS)行双侧扩大开窗减压26例,并与同期施行的全椎板切除术19例进行比较。临床资料1994年6月~2001年6月手术治疗并获得随访的LSS患者45例。男24例，女21例，年龄41~72岁，病程5个月~12年。狭窄部位：L4~L532例，L5~S128例，L3~L47例。单节段狭窄28例，双节段12例，3节段5例。主要临床表现：腰痛、下肢麻痛、间歇性跛行、膀胱直肠功能障碍、下肢肌萎缩和肌力下降等。经影像学检查证实均为退行性LSS。采用自椎板间孔双侧扩大开窗术26例，男15例，女11例，平均年龄51岁，术前平均病…     

维生素D受体在糖尿病肾病足细胞损伤及蛋白尿缓解中的作用

目的探讨维生素D受体(VDR)在糖尿病肾病(DKD)足细胞中的表达水平及在足细胞损伤及蛋白尿缓解中的作用。方法(1)本研究纳入了65例诊断患有2型糖尿病(伴或不伴蛋白尿)的患者,并纳入了25例年龄和性别相匹配的健康体检者为对照组。根据白蛋白/肌酐(ACR)的尿排泄比例对2型糖尿病患者进行分组,分别为无蛋白尿(ACR<30 mg/g,n=24)、微量白蛋白尿(ACR 30~300 mg/g,n=18)和临床蛋白尿(ACR>300 mg/g,n=23)。另选择25例经肾活检确诊的DKD患者作为DKD组。正常肾脏组织标本均取自泌尿外科同一时期肾脏肿瘤切除患者10例。将各组检测指标进行对比,同时采用实时定量PCR、ELISA法和免疫组化法检测VDR在各组患者的血液、尿液样本和肾脏组织中的表达情况,以及使用Pearson相关分析分析VDR与尿蛋白的相关性。(2)在2型糖尿病肾病小鼠模型中对上述结果进行验证,将遗传背景均为C57BLKs/J的雄性db/db小鼠及同窝出生的db/m小鼠,随机分为正常对照组(A组)、DKD对照组(B组)、DKD二甲基亚砜处理组(C组)、DKD帕立骨化醇(VDR激动剂)处理组(D组),C、D组连续腹腔注射处理8周,对照组不做任何处理。小鼠10周龄时开始连续干预8周,在小鼠22周龄(开始干预后12周)检测各组小鼠体重、血、尿生化指标对比;Western印迹法检测β⁃catenin、VDR的变化;免疫荧光观察足细胞标志蛋白podocin及足细胞损伤蛋白α⁃SMA的表达变化。结果(1)与正常健康对照组相比,无蛋白尿组、微量白蛋白尿组和临床蛋白尿组的糖尿病患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05);与无蛋白尿组的糖尿病患者相比,微量白蛋白尿组和临床蛋白尿组的糖尿病患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05)。(2)与正常健康对照组相比,无蛋白尿糖尿病组和DKD组患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05);与无蛋白尿糖尿病组患者相比,DKD组患者血浆中VDR的mRNA和蛋白水平亦较低(均P<0.05)。(3)免疫组化结果显示,DKD组肾组织中VDR的表达明显少于正常对照组。(4)DKD患者血浆中VDR mRNA相对水平与ACR呈负相关(r=-0.342,P<0.05)。(5)各组尿液上清液中VDR的水平与血浆中的水平呈相反趋势。(6)Western印迹结果显示,B组、C组肾小球足细胞β⁃catenin蛋白表达高于D组(均P<0.05),VDR蛋白的表达低于D组(均P<0.05);免疫荧光结果显示,B组、C组肾小球足细胞podocin的表达低于D组(均P<0.05),α⁃SMA的表达高于D组(均P<0.05)。结论VDR高表达缓解DKD足细胞损伤及蛋白尿。     

Anterior Interosseous Nerve Palsy After Shoulder Arthroscopy Treated With Surgical Decompression: A Case Series and Systematic Review of the Literature

Background: Anterior interosseous nerve (AIN) palsy is a very uncommon cause of upper extremity pain and weakness that comprises less than 1% of all upper extremity nerve palsies. Rarely reported but also mentioned in the literature is AIN palsy after shoulder arthroscopy. Methods: A systematic review of the literature to date using PubMed was conducted to identify patients who suffered AIN palsy after shoulder arthroscopy procedures. Articles included met the following criteria: (1) published in English; (2) primary presentation of the data; (3) patients had undergone shoulder arthroscopy before developing symptoms of AIN palsy; and (4) diagnosis was confirmed with clinical symptoms of AIN palsy. Measured outcomes included patient demographics, specific shoulder procedure, anesthesia procedure, intra-operative patient positioning, intra-operative compressive dressing, intra-operative traction, surgical versus conservative treatment, abnormal findings during decompression procedure, proposed mechanism of injury, and follow-up. Results: The search yielded 6 articles, of which 4 (13 cases) met inclusion criteria. An additional 2 cases were included in this report totaling 15 cases. The average patient age was 49 years (range: 31-64) with 73% males. At average follow-up of 24 months, 67% of patients experienced complete resolution of symptoms—more than half of which underwent surgical decompression. Patients who failed to progress experienced weakness of the flexor digitorum profundus and flexor pollicis longus muscles. Conclusions: Proposed injury mechanisms for AIN palsy after shoulder arthroscopy range from mechanical trauma, compressive hematoma, and direct anesthetic neurotoxicity. Management should be directed by clinical symptoms, imaging, and patient factors with majority of patients expected to have excellent clinical outcomes.     

不同尿钙水平的Gitelman综合征患者临床特点比较

目的观察不同尿钙水平Gitelman综合征(GS)患者的临床特点,探讨尿钙在GS疾病临床分型中的价值。方法收集2016—2018年来自中国国家罕见病注册系统(NRSC)、在北京协和医院行SLC12A3基因检测诊断为GS患者的临床资料,分析其尿钙特点,比较不同尿钙水平患者的临床和实验室检查指标。氢氯噻嗪试验按照标准操作流程进行,测定患者基线和用药后3 h内氯离子排泄分数改变量的最大值(ΔFECl)。结果共有83例GS患者被纳入研究,其中低尿钙患者53例(63.86%)。低尿钙组尿钙/肌酐比明显低于非低尿钙组[(0.085±0.058)mmol/mmol比(0.471±0.284)mmol/mmol,t=7.349,P<0.001]。两组患者在年龄、性别、估算肾小球滤过率、血压、血尿电解质水平、代谢性碱中毒方面差异均无统计学意义。低尿钙组患者乏力(χ2=4.595,P=0.032)及多尿(χ2=5.778,P=0.016)发生比例低于非低尿钙组,两组患者在其他临床症状方面差异无统计学意义。低尿钙和非低尿钙组各有16例患者行氢氯噻嗪试验,中位ΔFECl结果分别为0.539%(0.430%,1.283%)和0.829%(0.119%,1.298%),均提示对氢氯噻嗪无反应,组间差异无统计学意义(U=130.000,P=0.956)。结论GS患者中低尿钙比例为63.86%,尿钙水平与疾病临床表型、NCC功能损伤严重程度之间均无明确相关性。     

Role of Conventional and Diffusion-Weighted Magnetic Resonance Imaging of Spinal Treatment Protocol for Hydatid Disease

Objective:

To demonstrate the role of magnetic resonance imaging (MRI) in determining the treatment protocol for hydatid disease of the spine.

Design:

Case report; literature review.

Findings:

Diffusion-weighted MRI can help differentiate complicated infected hydatidosis from abscesses, epidermoid cysts from arachnoid cysts, and benign from malignant vertebral compression fractures. It is also helpful in differentiating between abscesses and necrotic tumors.

Conclusion:

Diffusion-weighted MRI can help differentiate between infections requiring immediate surgery and those that can be treated medically with antihelmintic treatment.     

Fibrinogen-thrombin collagen patch reinforcement of highrisk colonic anastomoses in rats

AIM To evaluate the effectiveness of human fibrinogenthrombin collagen patch(TachoSil~?) in the reinforcement of high-risk colon anastomoses.METHODS A quasi-experimental study was conducted in Wistar rats(n = 56) that all underwent high-risk anastomoses(anastomosis with only two sutures) after colectomies. The rats were divided into two randomized groups: Control group(24 rats) and treatment group(24 rats). In the treatment group, high-risk anastomosis was reinforced with TachoSil~? (a piece of Tacho Sil? was applied over this high-risk anastomosis, covering the gap). Leak incidence, overall survival, intra-abdominal adhesions, and histologic healing of anastomoses were analyzed. Survivors were divided into two subgroups and euthanized at 15 and 30 d after intervention in order to analyze the adhesions and histologic changes. RESULTS Overall survival was 71.4% and 57.14% in the TachoSil~? group and control group, respectively(P = 0.29); four rats died from other causes and six rats in the treatment group and 10 in the control group experienced colonic leakage(P 0.05). The intra-abdominal adhesion score was similar in both groups, with no differences between subgroups. We found non-significant differences in the healing process according to the histologic score used in both groups(P = 0.066).CONCLUSION In our study, the use of TachoSil~? was associated with a non-statistically significant reduction in the rate of leakage in high-risk anastomoses. TachoSil~? has been shown to be a safe product because it does not affect the histologic healing process or increase intra-abdominal adhesions.     

Fluorescence in the Sclera,Nails, and Teeth Secondary to Favipiravir Use for COVID-19 Infections

Favipiravir, an antiviral agent originally used for influenza infections, has become popular due to its beneficial signals in coronavirus disease. It is currently used in some countries within COVID-19 treatment protocols. This is an initial report of favipiravir-related fluorescence observed in three healthcare providers working in the same ward in our hospital. All three individuals had been diagnosed with COVID-19 two months earlier and were treated with favipiravir. None of the three individuals received hydroxychloroquine or tetracyclines. Wood’s light examination led to an incidental discovery of favipiravir-induced fluorescence involving the sclera, nails, and teeth. In all patients, white linear, square, and band-like specks of fluorescence were noticed on the sclera of both eyes, some teeth, and the proximal part of all fingernails and toenails. Exposure of the eyes to the Wood’s light was for a brief duration of 3 to 5 seconds during examination and photodocumentation. Favipiravir might cause bright white fluorescence of nails, sclera, and teeth, detectable by Wood’s light even two months after its cessation.     

Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers

BACKGROUND: Sugammadex rapidly reverses rocuronium- and vecuronium-induced neuromuscular block. To investigate the effect of combination of sugammadex and rocuronium or vecuronium on QT interval, it would be preferable to avoid the interference of anaesthesia. Therefore, this pilot study was performed to investigate the safety, tolerability, and plasma pharmacokinetics of single i.v. doses of sugammadex administered simultaneously with rocuronium or vecuronium to anaesthetized and non-anaesthetized healthy volunteers. METHODS: In this phase I study, 12 subjects were anaesthetized with propofol/remifentanil and received sugammadex 16, 20, or 32 mg kg(-1) combined with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1); four subjects were not anaesthetized and received sugammadex 32 mg kg(-1) with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1) (n=2 per treatment). Neuromuscular function was assessed by TOF-Watch SX monitoring in anaesthetized subjects and by clinical tests in non-anaesthetized volunteers. Sugammadex, rocuronium, and vecuronium plasma concentrations were measured at several time points. RESULTS: No serious adverse events (AEs) were reported. Fourteen subjects reported 23 AEs after study drug administration. Episodes of mild headache, tiredness, cold feeling (application site), dry mouth, oral discomfort, nausea, increased aspartate aminotransferase and gamma-glutamyltransferase levels, and moderate injection site irritation were considered as possibly related to the study drug. The ECG and vital signs showed no clinically relevant changes. Rocuronium/vecuronium plasma concentrations declined faster than those of sugammadex. CONCLUSIONS: Single-dose administration of sugammadex 16, 20, or 32 mg kg(-1) in combination with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1) was well tolerated with no clinical evidence of residual neuromuscular block, confirming that these combinations can safely be administered simultaneously to non-anaesthetized subjects. Rocuronium and vecuronium plasma concentrations decreased faster than those of sugammadex, reducing the theoretical risk of neuromuscular block developing over time.     

罗伊适应模式对腹股沟疝无张力疝修补术后恢复情况的影响

目的探讨罗伊适应模式对患者腹股沟疝无张力疝修补术后恢复情况的影响。 方法将2016年1月至2019年5月在秦皇岛市第二医院择期进行无张力修补术治疗的120例腹股沟疝患者，按照随机数字法分为对照组和观察组，每组各60例。对照组采用常规护理治疗，观察组在对照组的基础上采用罗伊适应模式。比较2组患者的术后临床指标、心理状态、围手术期并发症发生情况及满意度。 结果术后观察组患者的首次排气时间、恢复正常饮食时间、离床活动时间和术后住院时间均低于对照组（P<0.05）；术后观察组患者的抑郁自评量表（SDS）和焦虑自评量表（SAS）评分显著低于对照组（P<0.05）；术后2组患者均无切口感染发生，2组患者尿潴留、急性疼痛、认知功能障碍、发热、血肿等发生率相比无统计学差异（P>0.05）；术后观察组患者护理满意度为96.67%，显著高于对照组的83.33%（P<0.05）。 结论在常规护理的基础上，罗伊适应模式用于患者腹股沟疝无张力修补围手术期，能有效改善术后患者的焦虑/抑郁情绪，不增加围手术期并发症，促进术后患者的恢复及提高治疗满意度。     

Factors Associated With Reoperation After Silicone Proximal Interphalangeal Joint Arthroplasty

Background: Silicone proximal interphalangeal (PIP) joint arthroplasty has a high revision rate. It has been suggested that persistent ulnar deviation and joint instability influence the durability of PIP silicone arthroplasties. The goal of this study was to evaluate what factors are associated with reoperation after silicone PIP arthroplasty. Methods: We retrospectively evaluated all adult patients who underwent PIP silicone arthroplasty between 2002 and 2016 at one institutional system for inflammatory-, posttraumatic-, and primary degenerative arthritis. After manual chart review, we included 91 patients who underwent 114 arthroplasties. Fingers operated included 14 index, 41 middle, 38 ring, and 21 small fingers. Results: The overall reoperation rate was 14% (n = 16). Non-Caucasian race (P = .040), smoking (P = .022) and PIP silicone arthroplasty for post-traumatic osteoarthritis (P = .021) were associated with reoperation. The 1-, 5- and 10-year implant survival rates were 87%, 85%, and 85%, respectively. Conclusion: Caution should be exercised when considering PIP silicone arthroplasty of the index finger or in patients with post-traumatic osteoarthritis. It may be worthwhile addressing smoking behavior before pursuing silicone PIP arthroplasty.     

血浆凝血因子VIII水平与IgA肾病患者临床病理改变及预后的关系

目的探讨血浆凝血因子VIII(factor VIII,FVIII)水平与IgA肾病(IgAN)患者临床参数及预后的关系。方法收集2016年1月至2016年12月中南大学湘雅二医院确诊的IgAN患者的临床资料。按照时间依赖的受试者工作特征曲线(ROC)得出的血浆FVIII预测IgAN预后的临界值,将患者分为高FVIII组(FVIII>140.50%)和低FVIII组(FVIII≤140.50%),比较两组患者肾活检时基线临床参数的差异。以估算肾小球滤过率(eGFR)下降≥30%或进入终末期肾脏病(ESRD)为终点事件,采用Kaplan-Meier生存曲线及Cox回归方程法分析血浆FVIII水平对IgAN患者预后的影响。结果共93例IgAN患者纳入本研究,中位随访时间为35.15(33.77,36.76)个月,12例(12.90%)患者发生终点事件。高FVIII组患者年龄、血肌酐、尿素氮、血三酰甘油、血总胆固醇、血浆纤维蛋白原、D-二聚体、24 h尿蛋白量、蛋白C、蛋白S和eGFR下降速率高于低FVIII组(均P<0.05);eGFR、血白蛋白、中位随访时间低于低FVIII组(均P<0.05)。Kaplan-Meier生存分析结果显示,与低FVIII组比较,高FVIII组患者肾脏累积生存率降低(χ2=5.635,P=0.018)。在校正收缩压、eGFR、尿蛋白、肾小管萎缩/间质纤维化程度等因素后,多因素Cox回归分析结果显示,高血浆FVIII水平是IgAN患者肾脏预后不良的独立危险因素(HR=4.147,95%CI 1.055~16.308,P=0.042)。结论血浆FVIII水平与IgAN患者临床指标及预后相关,高血浆FVIII水平是IgAN患者肾脏预后不良的独立危险因素。